|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
0.2500 USD |
-3.29% | -3.88% | -55.56% | |
April 04, 2025 at 05:59 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Elevation Oncology Inc – To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 – SEC Filing |
Apr. 04 |
RE |
|
Stephens Downgrades Elevation Oncology to Equal Weight From Overweight, Adjusts Price Target to $1 From $5 |
Mar. 24 |
MT |
|
Wedbush Downgrades Elevation Oncology to Neutral From Outperform, Cuts Price Target to $1.60 From $5 |
Mar. 21 |
MT |
|
Leerink Downgrades Elevation Oncology to Market Perform From Outperform, Adjusts Price Target to $1 From $9 |
Mar. 21 |
MT |
|
Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10 |
Mar. 21 |
MT |
|
Sector Update: Health Care Stocks Decline Pre-Bell Thursday |
Mar. 20 |
MT |
|
Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell |
Mar. 20 |
MT |
|
Elevation Oncology, Inc. to Discontinue Development of EO-3021 |
Mar. 20 |
CI |
|
Elevation Oncology, Inc. Announces Step Down of Valerie M. Jansen as Chief Medical Officer, Effective March 31, 2025 |
Mar. 20 |
CI |
|
Elevation Oncology, Inc. Implements A Workforce Reduction of Approximately 70% |
Mar. 20 |
CI |
|
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements |
Mar. 06 |
RE |
|
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 06 |
CI |
|
Aadi Bioscience Appoints David Dornan, Phd, as Chief Scientific Officer |
Feb. 18 |
CI |
|
Elevation Oncology, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective February 17, 2025 |
Jan. 31 |
CI |
|
Elevation Oncology Advances EO-3021 and EO-1022 ADC Programs with Promising Phase 1 Data and Upcoming Milestones |
Jan. 13 |
CI |
|
William Blair Initiates Elevation Oncology at Outperform |
Jan. 03 |
MT |
|
Elevation Oncology, Inc. Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-Expressing Solid Tumors |
Dec. 12 |
CI |
|
Elevation Oncology, Inc. Presents Preclinical Proof-Of-Concept Data Supporting Combination Potential of Eo-3021 with Vegfr2 or Pd-1 Inhibitors At Esmo Immuno-Oncology Annual Congress 2024 |
Dec. 05 |
CI |
|
Earnings Flash (ELEV) ELEVATION ONCOLOGY Posts Q3 Loss $-0.22 |
Nov. 06 |
MT |
|
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 06 |
CI |
|
Elevation Oncology Gets FDA Fast-Track Designation for EO-3021 |
24-09-23 |
DJ |
|
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to S&P Global BMI Index |
24-09-22 |
CI |
|
Affimed N.V. Announces Chief Executive Officer Changes |
24-09-03 |
CI |
|
Elevation Oncology, Inc. – Special Call |
24-08-06 |
|
|
Elevation Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-06 |
CI |
ELEV: Dynamic Chart
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
More about the company
Buy
Last Close Price
0.2585USD
Average target price
1.060USD
Spread / Average Target
+310.06%
Consensus
